27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

Transient Ischemic Attack (TIA): The Modern Tissue-Based Definition & Pathophysiology

Transient Ischemic Attack (TIA) is a medical emergency that serves as a critical harbinger of impending cerebral infarction. Approximately 10% to 15% of patients who experience a TIA will suffer a completed ischemic stroke within 90 days, with half of those strokes occurring within the first 48 hours following the index event. Prompt recognition, rapid risk stratification, and emergent secondary prevention dramatically reduce this risk by up to 80%.

The Shift: Time-Based vs. Tissue-Based Definitions

For decades, the World Health Organization defined TIA using an arbitrary time-based definition: a sudden focal neurological deficit of presumed vascular etiology that resolved completely within 24 hours. Advances in neuroimaging have rendered this definition obsolete.

• The Modern Tissue-Based Definition (AHA/ASA): "A transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction."
• The Biological Rationale: Diffusion-Weighted Imaging (DWI) on Magnetic Resonance Imaging (MRI) is exquisitely sensitive to acute cytotoxic edema. High-resolution MRI reveals that up to 30% to 50% of patients whose clinical symptoms resolve completely in <24 hours have distinct focal hyperintensities on DWI, representing true microscopic ischemic cerebral infarction. Under contemporary guidelines, any patient with objective radiographic evidence of acute infarction is classified as having suffered an Ischemic Stroke (Cerebral Infarction), regardless of whether their symptoms lasted 15 minutes or 2 hours. The diagnosis of true TIA is reserved strictly for patients with transient focal ischemic symptoms AND a completely normal DWI-MRI.

                  TRADITIONAL vs CONTEMPORARY TIA DEFINITION

  TRADITIONAL (TIME-BASED)             CONTEMPORARY (TISSUE-BASED)
  ──────────────────────────────────────────────────────────────────────────
  • Symptoms resolve in < 24 hours     • Symptoms transient (focal ischemia)
  • Neuroimaging status ignored        • MANDATORY: No evidence of acute
  • Masks micro-infarctions as benign    infarction on Diffusion-Weighted MRI
  • Obsolete in modern guidelines      • DWI positive = ISCHEMIC STROKE
                                       • DWI negative = TRUE TIA

Vascular Territories & Clinical Phenotypes

TIAs produce sudden-onset, focal "negative" deficits corresponding to discrete arterial territories:

1. Anterior Circulation (Carotid / Middle Cerebral / Anterior Cerebral Arteries):
   • Middle Cerebral Artery (MCA): Unilateral motor weakness (face and arm > leg), unilateral sensory loss, expressive dysphasia (Broca's) or receptive aphasia (Wernicke's) in dominant hemisphere, or hemispatial neglect in non-dominant hemisphere;
   • Anterior Cerebral Artery (ACA): Contralateral lower extremity weakness and sensory loss (leg > arm), abulia, gait apraxia, or urinary incontinence;
   • Ophthalmic / Retinal Artery: Amaurosis Fugax (transient monocular vision loss): Sudden, painless loss of vision in one eye, characteristically described as a "black shade or curtain descending over the visual field," lasting 2 to 15 minutes, caused by temporary microembolization of retinal arterioles from an ipsilateral carotid atheroma.
2. Posterior Circulation (Vertebrobasilar / Posterior Cerebral Arteries):
   • Posterior Cerebral Artery (PCA): Contralateral homonymous hemianopia with macular sparing, visual agnosia;
   • Vertebrobasilar System: Vertigo, ataxia, dysarthria, diplopia, dysphagia, or bilateral limb weakness. Clinical Pearl: Isolated lightheadedness, syncope, or dizziness without other brainstem/cerebellar signs is rarely attributable to a posterior circulation TIA.

---

The ABCD2 Clinical Prediction Score

The ABCD2 score is a validated clinical prediction tool developed to quantify the short-term risk of recurrent stroke within 48 hours following a suspected TIA. It guides decisions regarding emergency hospitalization, monitoring, and urgent intervention.

Scoring Components & Point Allocation

                         THE ABCD2 SCORING SYSTEM

  CRITERION             CLINICAL PARAMETER                              POINTS
  ──────────────────────────────────────────────────────────────────────────
  A - Age               Age ≥ 60 years                                    1
  ──────────────────────────────────────────────────────────────────────────
  B - Blood Pressure    Initial Systolic BP ≥ 140 mmHg                    1
                        OR Initial Diastolic BP ≥ 90 mmHg
  ──────────────────────────────────────────────────────────────────────────
  C - Clinical Features Unilateral motor weakness (with or without         2
                        speech disturbance)
                        Speech disturbance WITHOUT unilateral weakness    1
                        Other symptoms (e.g., isolated sensory)          0
  ──────────────────────────────────────────────────────────────────────────
  D - Duration          Symptom duration ≥ 60 minutes                     2
                        Symptom duration 10 to 59 minutes                 1
                        Symptom duration < 10 minutes                     0
  ──────────────────────────────────────────────────────────────────────────
  D - Diabetes          Pre-existing history of Diabetes Mellitus         1
  ──────────────────────────────────────────────────────────────────────────
  TOTAL SCORE: 0 to 7 points

Risk Stratification & Predicted Stroke Probability

Criteria for Urgent Hospital Admission

Current AHA/ASA guidelines strongly recommend hospital admission (or placement in a specialized rapid-access TIA observation unit) for patients presenting with suspected TIA within 72 hours if they meet ANY of the following:

1. ABCD2 score ≥ 4 (moderate to high 48-hour stroke risk);
2. ABCD2 score 0 to 3 if the mandatory diagnostic workup cannot be guaranteed and completed within 24 to 48 hours in the outpatient setting;
3. Crescendo TIAs (two or more distinct focal episodes occurring within a 72-hour window);
4. Objective evidence of acute focal brain ischemia on neuroimaging (DWI-positive);
5. Known or newly identified symptomatic carotid stenosis ≥50%;
6. Documented high-risk cardioembolic source (e.g., atrial fibrillation, left ventricular thrombus, acute myocardial infarction, or severe cardiomyopathy).

---

Urgent Diagnostic Evaluation Algorithm (Within 24 to 48 Hours)

Every patient presenting with a suspected TIA must undergo a rapid, comprehensive diagnostic evaluation within 24 to 48 hours to identify the underlying etiology (large artery atherosclerosis, cardioembolism, small vessel lacunar disease, or rare etiologies) and initiate targeted secondary prevention.

                      URGENT TIA DIAGNOSTIC PARADIGM

  1. BRAIN PARENCHYMA IMAGING
     • FIRST-LINE: Brain MRI with Diffusion-Weighted Imaging (DWI)
       *80-90% sensitive for micro-infarctions; detects cytotoxic edema*
     • ALTERNATIVE: Non-contrast Head CT (if MRI contraindicated or unavailable)
       *Rules out intracranial hemorrhage, subdural hematoma, mass*

  2. NEUROVASCULAR VESSEL IMAGING (Extracranial & Intracranial)
     • Modalities: CT Angiography (CTA) of Head/Neck, MRA, or Carotid Duplex US
     • Goal: Identify symptomatic internal carotid artery (ICA) stenosis
     • Symptomatic ICA Stenosis 70-99%: URGENT Carotid Endarterectomy (CEA)
       within 14 days of symptom onset (ideally within 48-72 hours)

  3. CARDIAC EVALUATION
     • 12-Lead Electrocardiogram (ECG): Immediate screen for atrial fibrillation/flutter
     • Inpatient Continuous Telemetry: Minimum 24-48 hours
     • Prolonged Ambulatory Monitoring: 30-day mobile cardiac telemetry (MCOT)
       or external loop recorder in cryptogenic TIA (detects paroxysmal AF in 10-15%)
     • Transthoracic Echocardiogram (TTE) with Bubble Study: Evaluates for intracardiac
       thrombus, patent foramen ovale (PFO), atrial septal aneurysm, valvular vegetations

  4. LABORATORY EVALUATION
     • CBC (platelets), PT/INR, aPTT, Fasting Lipid Panel (LDL), HbA1c, CMP, Troponin

Neurovascular Imaging & Carotid Revascularization

Carotid artery atherosclerosis is responsible for approximately 15% to 20% of ischemic strokes. When an atheroma at the carotid bifurcation ulcerates or narrows the lumen, it generates recurrent artery-to-artery thromboemboli.

• Symptomatic Severe Internal Carotid Artery Stenosis (70% to 99% by NASCET criteria):
  • Urgent Carotid Endarterectomy (CEA) is strongly indicated within 14 days of the index ischemic event (optimally within 48 to 72 hours once clinical and neurological stability is established).
  • Evidence: Landmark trials (NASCET, ECST) proved that CEA reduces the 5-year absolute stroke risk by >16% (number needed to treat [NNT] ~6).
  • Carotid Artery Stenting (CAS): An effective alternative for patients with hostile neck anatomy (prior radical neck dissection, radiation arteritis, tracheostomy), severe tandem stenosis, or prohibitive cardiopulmonary surgical risk.
• Symptomatic Moderate Stenosis (50% to 69%):
  • CEA provides moderate benefit (NNT ~15-20), particularly in men, patients aged ≥75 years, and those with hemispheric (rather than retinal) symptoms; surgery should also be performed within 14 days.
• Mild Stenosis (<50%) or Complete Occlusion (100%):
  • Surgical revascularization is NOT indicated. Complete occlusion carries a high surgical complication risk with zero downstream flow to preserve; patients are managed with intensive medical therapy.

Cardiac Telemetry & Occult Atrial Fibrillation

Cardioembolism accounts for up to 25% of ischemic strokes and TIAs, with Atrial Fibrillation (AF) representing the predominant cause. Because paroxysmal AF is frequently asymptomatic and intermittent, a normal 12-lead ECG or brief 24-hour telemetry strip does not exclude the diagnosis. Landmark randomized trials (CRYSTAL AF, EMBRACE) demonstrated that extended ambulatory cardiac monitoring with a 30-day mobile cardiac outpatient telemetry (MCOT) or an implantable loop recorder detects occult paroxysmal atrial fibrillation in 10% to 15% of patients with cryptogenic TIA/stroke, fundamentally shifting management from antiplatelet therapy to oral anticoagulation.

---

Secondary Stroke Prevention Pharmacotherapy

Secondary prevention must be initiated immediately upon confirmation of TIA or minor stroke.

                 EVIDENCE-BASED SECONDARY PREVENTION REGIMEN

  ┌─────────────────────────────────────────────────────────────┐
  │ 1. DUAL ANTIPLATELET THERAPY (DAPT) - THE 21-DAY RULE        │
  │    • INDICATION: High-risk TIA (ABCD2 ≥ 4) or minor stroke  │
  │      (NIHSS ≤ 3) presenting within 24 hours of onset        │
  │    • REGIMEN: Aspirin 81 mg daily PLUS Clopidogrel 75 mg   │
  │      daily (with 300-600 mg clopidogrel loading dose)       │
  │    • DURATION: EXACTLY 21 DAYS (CHANCE & POINT trials)      │
  │    • DAY 22 ONWARD: Transition to single antiplatelet       │
  │      monotherapy lifelong (Aspirin 81 mg or Clopidogrel)    │
  └──────────────────────────────┬──────────────────────────────┘
                                 ▼
  ┌─────────────────────────────────────────────────────────────┐
  │ 2. HIGH-INTENSITY STATIN THERAPY                            │
  │    • INDICATION: All atherosclerotic non-cardioembolic TIA  │
  │    • REGIMEN: Atorvastatin 80 mg daily (or Rosuvastatin 40) │
  │    • TARGET: LDL-C reduction ≥50% AND absolute LDL < 70 mg/dL│
  │      (SPARCL trial); add Ezetimibe 10 mg if target unmet    │
  └──────────────────────────────┬──────────────────────────────┘
                                 ▼
  ┌─────────────────────────────────────────────────────────────┐
  │ 3. BLOOD PRESSURE OPTIMIZATION                              │
  │    • ACUTE PHASE (first 24-48h): Permissive hypertension;   │
  │      withhold antihypertensives unless BP > 220/120 mmHg    │
  │    • LONG-TERM TARGET: < 130/80 mmHg (PROGRESS trial)       │
  │    • PREFERRED AGENTS: ACE inhibitors, ARBs, Thiazide-like  │
  │      diuretics (Perindopril + Indapamide)                   │
  └──────────────────────────────┬──────────────────────────────┘
                                 ▼
  ┌─────────────────────────────────────────────────────────────┐
  │ 4. ORAL ANTICOAGULATION (IF ATRIAL FIBRILLATION DETECTED)   │
  │    • FIRST-LINE: DOACs (Apixaban 5 mg BID, Rivaroxaban      │
  │      20 mg daily, Dabigatran 150 mg BID, Edoxaban 60 mg)    │
  │    • DOACs preferred over Warfarin (>50% reduction in ICH)  │
  │    • DISCONTINUE antiplatelets when starting DOAC           │
  └─────────────────────────────────────────────────────────────┘

1. Dual Antiplatelet Therapy (DAPT): The CHANCE and POINT Landmark Evidence

• The Clinical Paradigm: In patients with high-risk TIA (ABCD2 score ≥ 4) or acute minor ischemic stroke (NIHSS score ≤ 3) who present within 24 hours of symptom onset, combining two antiplatelet agents with complementary mechanisms provides superior inhibition of platelet aggregation during the peak window of stroke recurrence.
• Landmark Clinical Trials:
  1. CHANCE Trial (NEJM 2013): Conducted in China with 5,170 patients randomized to Aspirin + Clopidogrel for 21 days versus Aspirin monotherapy. DAPT significantly reduced 90-day recurrent stroke (8.2% vs. 11.7%; Hazard Ratio 0.68, p<0.001)—a 32% relative risk reduction—with no increase in major hemorrhagic events.
  2. POINT Trial (NEJM 2018): International multicenter trial with 4,881 patients randomized to Aspirin + Clopidogrel for 90 days versus Aspirin monotherapy. DAPT significantly reduced major ischemic events (5.0% vs. 6.5%; HR 0.75). However, major hemorrhage was significantly higher in the DAPT group (0.9% vs. 0.4%; HR 2.32). Crucially, secondary time-to-event analysis revealed that the ischemic benefit was concentrated entirely within the first 21 days, whereas the risk of major hemorrhage continued to accumulate beyond day 21.
• CRITICAL BOARD RULE: DAPT DURATION IS EXACTLY 21 DAYS: DAPT with Aspirin 81 mg daily PLUS Clopidogrel 75 mg daily (initiated with an oral loading dose of 300 to 600 mg clopidogrel) must be continued for 21 days. At day 21, clopidogrel is stopped, and the patient is transitioned to lifelong single antiplatelet monotherapy (Aspirin 81 mg daily, Clopidogrel 75 mg daily, or Aspirin 25 mg / Extended-Release Dipyridamole 200 mg BID). Continuing DAPT beyond 21 days confers zero additional ischemic benefit while significantly elevating the risk of life-threatening intracranial and gastrointestinal hemorrhage.

2. High-Intensity Statin Therapy

• All patients with non-cardioembolic TIA or ischemic stroke of atherosclerotic origin must be started immediately on high-intensity statin therapy, regardless of their baseline cholesterol level.
• Regimen: Atorvastatin 80 mg PO daily (or Rosuvastatin 20 to 40 mg daily).
• Evidence & Targets: The landmark SPARCL trial (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) proved that high-dose atorvastatin reduced the 5-year absolute risk of recurrent stroke by 16%. The therapeutic target is an LDL-C reduction of ≥50% from baseline and an absolute LDL-C level <70 mg/dL (or <55 mg/dL in patients with multiple major cardiovascular events). If the target is not achieved on maximally tolerated statin therapy, add Ezetimibe 10 mg daily.

3. Blood Pressure Optimization

• Acute Phase (First 24 to 48 Hours): In the acute post-TIA period, autoregulation of cerebral blood flow in the ischemic penumbra is impaired. Rapid, aggressive blood pressure lowering can induce penumbral hypoperfusion and convert viable tissue into completed infarction. Antihypertensive therapy is withheld unless blood pressure exceeds 220/120 mmHg or there are severe end-organ emergencies (acute coronary syndrome, aortic dissection, hypertensive encephalopathy).
• Chronic Maintenance Phase: Once stability is confirmed, long-term blood pressure control is the single most powerful intervention to prevent recurrent stroke. The goal is <130/80 mmHg. Preferred regimens include an ACE inhibitor or ARB paired with a thiazide-like diuretic (e.g., perindopril and indapamide, proven in the PROGRESS trial).

4. Oral Anticoagulation for Cardioembolic TIA

• If cardiac telemetry, Holter monitoring, or echocardiography reveals atrial fibrillation, atrial flutter, or intracardiac thrombus, antiplatelet therapy is discontinued and replaced by therapeutic oral anticoagulation.
• Direct Oral Anticoagulants (DOACs)—Apixaban (5 mg BID), Rivaroxaban (20 mg daily), Dabigatran (150 mg BID), or Edoxaban (60 mg daily)—are the preferred first-line agents over warfarin. DOACs provide equivalent or superior stroke prevention with a >50% reduction in catastrophic intracranial hemorrhage.
• Warfarin (target INR 2.0 to 3.0) is strictly reserved for patients with mechanical prosthetic heart valves or moderate-to-severe rheumatic mitral stenosis.
• Antiplatelet Cessation: In patients initiated on oral anticoagulants for atrial fibrillation, concurrent antiplatelet therapy must be discontinued unless the patient has had a recent percutaneous coronary intervention (within 1-12 months), because combining antiplatelets with anticoagulants doubles the risk of major bleeding without lowering ischemic stroke rates.